Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19.

Enric Monreal (✉ enricmonreal@outlook.com)

Hospital Universitario Ramón y Cajal, Madrid, Spain. <https://orcid.org/0000-0003-3293-0125>

Susana Sainz de la Maza

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Pedro Gullón

Public Health and Epidemiology Research Group. Universidad de Alcalá, Madrid, Spain.

Elena Natera-Villalba

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Juan Luis Chico-García

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Álvaro Beltrán-Corbellini

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Javier Martínez-Sanz

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Nuria García-Barragán

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Javier Buisán

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Rafael Toledano

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Araceli Alonso-Canovas

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Paula Pérez-Torre

Hospital Universitario Ramón y Cajal, Madrid, Spain.

María Consuelo Matute-Lozano

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Jose Luis López-Sendón

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Guillermo García-Ribas

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Íñigo Corral

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Jesús Fortún

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Beatriz Montero-Errasquín

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Luis Manzano

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Luis Máiz-Carro

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Lucienne Costa-Frossard

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Jaime Masjuan

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Research Article

Keywords: COVID-19, severe acute respiratory syndrome coronavirus 2, immunosuppression

Posted Date: September 1st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-27095/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that has spread rapidly worldwide. The role of immunosuppression among COVID-19 patients has not been elucidated and management may be challenging.

OBJECTIVE: To assess differences in severe outcomes of hospitalized patients with COVID-19 according to immune system state.

DESIGN: Retrospective single-center observational study with confirmed COVID-19 patients admitted to Hospital Universitario Ramón y Cajal from March 18, 2020 to April 04, 2020. The final date of follow-up was April 09, 2020.

PARTICIPANTS: Confirmed COVID-19 patients.

MAIN MEASURES: The primary endpoint was development of moderate-severe acute respiratory distress syndrome (ARDS). Time to moderate-severe ARDS, the need for mechanical or non-invasive ventilation (MV/NIV), death, and a composite of death or MV/NIV were secondary endpoints.

KEY RESULTS: Of 138 patients included, 27 (19.6%) were immunosuppressed (IS), with 95 (68.8%) male patients and a median (Q1, Q3) age of 68 (54–78) years. Among the baseline characteristics, no relevant or significant differences were observed between IS and non-immunosuppressed (non-IS) patients, detecting a non-severe immunosuppression among IS. A significantly lower proportion of IS patients (22.2% [95%CI, 9.8–43.0%]) compared to non-IS patients (49.5% [95%CI, 40.2–58.9%]) developed moderate-severe ARDS, in both unadjusted (OR 0.29 [95%CI, 0.11–0.76], $p=0.014$) and adjusted (aOR 0.16 [95%CI, 0.05–0.55], $p=0.004$) analyses. After stratifying by pathologies, only IS autoimmune diseases remained significant (aOR 0.12 [95%CI, 0.03–0.57], $p=0.007$). Non-significant trends toward a longer time to moderate or severe ARDS, a lower need for MV/NIV, and a lower risk of death or MV/NIV were detected in IS.

CONCLUSIONS: In our cohort of COVID-19 patients, non-severe immunosuppression was associated with a lower risk of moderate-severe ARDS, especially among AD. This suggests a potential protective effect

from a hypothesized host hyper-inflammatory response and warrants reconsideration of management of IS patients.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known to cause Coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China¹ and has rapidly spread worldwide.

The first published data from China indicated that nearly one-third of patients may subsequently develop acute respiratory distress syndrome (ARDS), which results in a higher likelihood of needing mechanical ventilation (MV) and of death². Older age and the presence of comorbidities have been associated with a higher risk of ARDS, and with progression from ARDS to death³.

Patients with immunosuppression were initially thought to be at an increased risk of severe COVID-19. However, preliminary data suggest a three-stage SARS-CoV-2 infection, with two distinct but overlapping subsets⁴: the first triggered by the virus itself and the second consisting of a deregulated and excessive host immune response, which appears to be the main driver of lung tissue damage⁵. Therefore, we hypothesize that a weaker immune response to the virus might prevent immunosuppressed patients from developing a severe disease.

We aimed to evaluate differences in the inflammatory response during COVID-19 between immunosuppressed (IS) and non-immunosuppressed (non-IS) patients by assessing the risk of ARDS, the need for mechanical (MV) or non-invasive ventilation (NIV), death and the length of hospitalization.

Methods

Study design

This single-center, retrospective, observational study was performed at Hospital Universitario Ramón y Cajal, Madrid, a tertiary hospital in the region with the highest incidence of cases of the pandemic of COVID-19 in Spain⁶. Due to the emergency outbreak, the hospital was completely restructured and nearly all the specialists of the Neurology department were assigned to attend COVID-19 patients. A multidisciplinary group of Internal Medicine, Infectious Diseases, and Neumology experts elaborated on clinical guidelines, which were strictly followed by all the physicians treating COVID-19 patients. All adult inpatients with confirmed or highly suspected SARS-CoV-2 infection from March 18, 2020 to April 4, 2020 attended by a selected group of multidisciplinary physicians were consecutively enrolled (Figure 1). For the analysis, only those with a laboratory-confirmed infection and a minimum of baseline and outcome variables available (detailed below) were included. According to the WHO guidance⁷, confirmation of SARS-CoV-2 was defined as a positive result of real-time reverse transcriptase–polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs. The RT-PCR assay was performed by expert microbiologists from the same center. The patients were followed-up with until April 9, 2020.

This study was approved by the institutional ethics board of Hospital Universitario Ramón y Cajal. Due to the nature of the retrospective chart review, the need for informed consent from individual patients was waived.

Data collection

The electronic medical records of the participants were reviewed by a trained team of physicians from Hospital Universitario Ramón y Cajal during the epidemic period, after selection based on the eligibility criteria. Baseline characteristics included were: demographics, medical history, comorbidities, laboratory examinations, radiological findings, and clinical and respiratory variables. Additionally, we included such variables as bacterial co-infection and treatments administered. Immunosuppressed patients were defined as those with an inherited or acquired immunodeficiency or taking any drug with an immunomodulatory or immunosuppressive effect (see Supplement Material for a complete description of all IS patients). Corticosteroids were considered immunomodulators at prednisone-equivalent dosages >10 to <40 mg/day, but immunosuppressants at ≥ 40 mg/day.

The primary endpoint was the development of moderate or severe acute respiratory distress syndrome (ARDS), defined according to the Berlin Definition⁸. Secondary endpoints were percentages of death among those with a final outcome, need for mechanical (MV) or non-invasive ventilation (NIV), a composite of need of MV/NIV or death, length of hospitalization to April 9, 2020, and time to moderate-severe ARDS between the cohorts.

Statistical analysis

Continuous variables were described using means and standard deviations or medians and quartiles depending on whether or not data were normally distributed. The Shapiro-Wilk test was used to test the normality of data distributions. Categorical variables were described using absolute and relative frequencies. The Fisher test was used to analyze categorical variables and the Mann-Whitney U test was used for quantitative variables. Logistic regression models were conducted to study the association between primary and secondary endpoints and immunosuppression; in the case of the length of hospitalization, we used linear regression instead. We performed both unadjusted (crude) and multivariate (adjusted) models, taking into account potential confounding factors (sex, age, and time from onset of symptoms to event or end of follow-up). As a secondary analysis, we performed Kaplan-Meier survival curves of time to moderate or severe ARDS with a log-rank test adjusted by immunosuppression status. A bivariate adjusted Cox proportional-hazards model was used to determine HR and 95% CIs on the development of the primary endpoint between both groups. All data analyses were conducted using R (R Core Team (2017), Version 3.6.3., R Foundation for Statistical Computing, Vienna, Austria). Statistical hypotheses were tested using $p < 0.05$ as the level of significance.

Results

From March 18, 2020 to April 4, 2020, 157 patients with highly suspected or confirmed COVID-19 were admitted and attended to by the treating physicians and were therefore selected for this study. After excluding those who did not fulfill the eligibility criteria (17 patients due to a negative test result for SARS-CoV-2 and 2 patients due to insufficient data), 138 patients were included in the analysis. From the final cohort, 19.6% (n=27) of patients were IS and 80.4% (n=111) were non-IS. Among IS patients, 63% (n=17) were diagnosed with an autoimmune disease (IS-AD) and 37% (n=10) were diagnosed with other diseases (IS-NAD) (Figure 1). Additional information about IS patients is provided in the Supplement Material. Table outlines the demographic, clinical and laboratory baseline characteristics of all patients and both groups. Overall, 68.8% (95 of 138 patients) were male and the median (Q1, Q3) age was 68 (54 – 78) years, distributed similarly among both cohorts. No statistically significant differences were observed between IS and non-IS in terms of comorbidities, excepting for subsidiary diseases of immunosuppression such as AD (59.3% vs. 2.7%, $p<0.001$) and organ transplant (18.5% vs. 0%, $p<0.001$). The median (Q1, Q3) time from onset of symptoms to admission was 7 (4 – 11) days and a similar respiratory situation was observed between both groups, with a median (Q1, Q3) SatO₂ of 93% (88 – 96%) on room air, PaO₂ (available in 92 patients, done mainly to those with a low SatO₂) of 57 (51 – 66) mmHg, and a PaO₂/FiO₂ of 267 (233 – 310) mmHg. Bilateral pneumonia was the most frequent radiological finding (70.4% vs. 84.7% in IS vs. non-IS, respectively, $p=0.19$), with a median (Q1, Q3) CURB-65 score of 1 (1 – 2) and 2 (1 – 2) ($p=0.48$), respectively. Laboratory examinations were practically identical, with a mild lymphopenia (median [Q1, Q3] 855 [620 – 1210] cells/ μ L). Nevertheless, a trend ($p=0.08$) toward a higher C-reactive protein among non-IS (median [Q1, Q3] of 119.1 [56.7 – 186.1]) compared to IS (74.5 [33.3 – 144.9] mg/L). Bacterial co-infection was infrequent in the overall population (14.5%) and the most frequently used treatments were hydroxychloroquine (98.6%) and lopinavir/ritonavir (70.4% vs. 88.2% [$p=0.033$] in IS and non-IS, respectively). Corticosteroids (48.2 vs. 64.9%) and the monoclonal antibodies Tocilizumab (3.7 vs. 13.5%) and Anakinra (0 vs. 2.7%) were more widely used during hospitalization in non-IS, although the differences were not statistically significant. Among treatment-induced IS patients, the immunosuppressive drug was discontinued at admission in 6 of 25 patients (24%). Based on baseline characteristics related to immunosuppression and laboratory findings observed, the grade of depletion of immune system of the IS cohort was considered non-severe.

Comparison of complications during hospitalization

The primary endpoint (development of moderate or severe ARDS) was significantly lower for IS patients (22.2% [95% CI, 9.8 to 43.0%]) compared to non-IS patients (49.5% [95% CI, 40.2 to 58.9%]), with a crude OR of 0.29 (95% CI, 0.11 to 0.76) ($p=0.014$). After adjusting by sex, age, and time from onset of symptoms to event or end of follow-up, the adjusted OR (aOR) showed a stronger protective effect for IS (aOR 0.16 [95% CI, 0.05 to 0.55]) ($p=0.004$). After stratifying by AD, significant differences were observed in the proportion of moderate-severe ARDS for IS-AD (17.7%) when compared to IS-NAD (30%). The

logistic regression model was therefore replicated, and a lower risk was detected only for IS-AD (aOR 0.12 [95% CI, 0.03 – 0.57], $p=0.007$), but not for IS-NAD (aOR 0.21 [95% CI, 0.03 – 1.53], $p=0.12$). An adjusted Cox regression was subsequently conducted, finding a non-significant trend toward a shorter time to moderate-severe ARDS in non-IS (mean [SD] 9.72 [± 4.40] days) compared to IS (mean [SD] 9.5 [± 5.26] days) (aHR 0.43 [95% CI, 0.19 – 1.00], $p=0.052$), despite a significant difference in the log-rank test ($p=0.03$) (Figure 3).

Although lower proportions were observed for IS patients, no statistically significant differences were detected in risk of need for MV/NIV (3.7% vs. 13%, aOR 0.18 [95% CI, 0.13 – 1.65], $p=0.13$) or in risk of a composite of need for MV/NIV or death (11.1% vs. 17.1%, aOR 0.33 [95% CI, 0.07 – 1.58], $p=0.17$) in IS compared to non-IS, respectively. A final outcome (death/discharge) was recorded in 79 patients (57.2%), with an overall mortality of 19% (95% CI, 11.65 – 29.4%). A comparison of both groups detected no significant differences between IS (21.4%) and non-IS (18.5%), with an adjusted OR of 0.67 (95% CI, 0.12 – 3.69) ($p=0.65$) (Figure 2). The median (Q1, Q3) stay was 9 (5 – 12) days for the overall population, with a trend toward a lower stay ($\beta = -2.45$ [95% CI, -4.99 to 0.08] days, $p=0.057$) for IS after adjusting by age and time from onset of symptoms to admission.

Discussion

In this retrospective, single-center, observational study with inpatients with COVID-19 in Madrid, Spain, a better outcome, in terms of lower risk to moderate or severe ARDS, was observed among a cohort of patients with non-severe immunosuppression as compared to non-IS. A trend toward a shorter time to moderate-severe ARDS and a shorter hospitalization were also observed. After stratifying by source of IS, the protective effect seemed to be mainly driven by AD. However, no differences in time to moderate-severe ARDS, need for MV/NIV, or a composite of MV/NIV and death were detected between IS and non-IS despite lower proportions for the first cohort. A comparison of both groups showed no differences in the death ratio.

Immunosuppression has been widely considered a risk factor for infections, with a higher incidence and a worse outcome, including those caused by a respiratory virus⁹. For example, influenza infection was observed to be associated with a higher risk of more hospitalizations, a longer length of virus shedding, a more severe disease, and complications requiring intensive care and MV¹⁰. Additionally, several studies consider immunosuppression to be a risk factor of a more severe disease in MERS-CoV infection¹¹⁻¹⁴. Previous works have already described risk factors predicting a worse outcome in COVID-19 patients, such as older age^{3, 15-17}, comorbidities (hypertension, diabetes, or vascular diseases)^{3, 15, 17}, -and laboratory findings, with special attention paid to those indicating hyperinflammation or cytokine storm syndrome^{18, 19}, like elevated serum D-dimer, ferritin, C-reactive protein, or interleukin (IL)-6 levels^{3, 15-17}. Nevertheless, none of these works has specifically assessed immunosuppression as a risk factor in COVID-19 patients. A population-based study in China evaluated cancer patients with recent surgery or chemotherapy, and found a higher risk of severe events²⁰. In addition, recent data about patients with

moderate or severe immunosuppression associated to haematologic malignancy^{21, 22} and solid organ transplant recipients^{23, 24} detected higher death ratios compared to general population. In line with these results, a large population-based study with over 17 million subjects developed in UK found a higher mortality among organ transplant, immunosuppression, haematological malignancies, and several autoimmune diseases²⁵. However, limitations to interpret these results are that all national COVID-19 inpatients are compared to about 40% of general population (with a potential selection bias) and no description about treatments and baseline characteristics of these groups is reported.

In our study, a lower proportion of IS patients developing moderate-severe ARDS was observed. We decided to assess this variable as a primary endpoint due to its higher specificity in detecting more inflammatory patients. This contrasts with previous data²¹⁻²⁵ about immunosuppression, but differences might reside in the grade of immunosuppression, being less severe in our cohort. To delve into a possible condition explaining these results, we further differentiated IS patients between those with an AD and those with other diseases (such as cancer or an organ transplant). A lower proportion was only observed for IS-AD patients but not for IS-NAD. In line with this result, a trend toward a lower proportion of MV/NIV or a composite of the need for MV/NIV was also detected, probably due to the lower risk of ARDS.

This data might be explained by pathophysiological findings about COVID-19, such as the three-stage classification model of SARS-CoV-2 infection proposed by Siddiqi et al.⁴, with two distinct but overlapping subsets. The first triggered by the virus itself and the second, occurring in a minority of patients, host-mediated and based on an excessive immune response, leading to ARDS, the need for MV, and, potentially death^{3, 16-18}. Pathophysiology similar to that of SARS-CoV has been hypothesized for SARS-CoV-2 infection²⁶, in which a marked elevation of cytokines of the Th1 cell-mediated immunity (such as interferon (IFN)- γ , IL-1, IL-6, and IL-12) and hyperinnate (neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN γ -inducible protein-10 [IP-10]) inflammatory response²⁷ have been observed. In COVID-19, both innate immune hyperactivation and adaptive immune dysregulation have been hypothesized to be responsible of ARDS²⁸. For this reason, several immunomodulatory drugs, such as corticosteroids, intravenous immune globulin, and cytokine inhibitors with a mild effect over immune system have been proposed depending on whether the hyperinflammation stage is suspected^{18, 19, 22}. Preliminary data suggest a potential benefit of methylprednisolone in terms of the risk of death after the development of ARDS³, though clinical trials are required before recommending this therapy. All these results support the notion that immunosuppression, at least if non-severe might confer a protective effect in the most severe stages of the disease. We found that the lowest risk of moderate-severe ARDS was detected in IS-AD patients. This contrasts with evidence of an increased risk of infections observed in AD, through the presence of neutralizing autoantibodies against pro-inflammatory cytokines. These autoantibodies may have the ability to interfere with key cytokine such as IL-6, IFN- γ , granulocyte/macrophage-colony stimulating factor (GM-CSF), IL-17, and IL-22 resulting in a lower Th1 and Th17 inflammatory response²⁹. We have not assessed the risk of infection by SARS-CoV-2 in IS patients. But it could be hypothesized that a complex interaction

between AD and a non-severe immunosuppression in COVID-19 could exert a protective effect of severe outcomes related to an innate immune hyperactivation.

No differences in death rate were observed in our cohort. The reasons for these results might be explained by the smaller sample size of patients with a final outcome, the short follow-up, or unknown confounding factors. For example, during cytokine storm syndrome, ARDS is not the single inflammatory complication observed, as evidence of multi-organ dysfunction, with acute cardiac injury³⁰ and liver and renal impairment^{3, 16, 17, 31}, has been described. This might be attributable to the widespread distribution of angiotensin converting enzyme 2 –the functional receptor for SARS-CoV-2– in multiple organs³². In addition, the results may be biased by the fact that IS patients may never get to MV/NIV, being considered too disabled, so they are more likely to die than non-IS patients. Also, several factors related to the development of ARDS that were not associated with death have been described³, which indicates that different pathophysiological changes –from hospital admission to the development of ARDS and from the development of ARDS to death- may exist.

Thus, our results might have relevance in terms of establishing recommendations for IS patients. Discontinuation of immunosuppressive drugs can be considered or suggested by either asymptomatic patients or treating physicians concerned about possible a worse course if a SARS-CoV-2 infection develops. But this may have implications with respect to diminishing the underlying disease control, with potential fatal outcomes in either cancer or organ transplant patients or the reactivation³³ or even rebound³⁴ of disease activity among autoimmune disorders. Taking this data into account, careful individual decision-making about maintaining immunosuppressive drugs must be performed in non-infected or even mild COVID-19 patients. Second, less aggressive anti-inflammatory management among IS patients might be contemplated, lowering the risk of bacterial co-infections. Third, social and preventive care recommendations might be reconsidered for these patients.

This study has several limitations. First, a potential selection bias might have occurred, as only a part of hospitalized patients (those attended by the treating physicians reported) were evaluated and IS might be admitted more easily by its own condition than non-IS. For this reason, patients directly admitted to ICU from the emergency room were not included. Second, this study was conducted at a single center with a limited sample size. Third, the cohort of IS patients is heterogeneous regarding diseases and immunosuppressive drugs, which may limit external validity to all type of IS patients. In addition, small sample size limits subgroup analyses by source of immunosuppression. Fourth, due to the lack of evidence-based treatment protocols, the treating physicians took different management approaches (especially with anti-viral drugs or corticosteroids), which could have altered the development of the outcomes. And finally, the retrospective character of the study and the short follow-up time warrant caution in interpreting the data. Further studies with a prospective design and a larger sample size, including outpatients, might gain a better understanding of the role that immunosuppression plays among COVID-19 patients.

In conclusion, in our cohort non-severe immunosuppression was associated with a lower risk of moderate-severe ARDS, a trend toward a reduced need for MV/NIV, a shorter hospitalization, and a longer time before moderate or severe ARDS occurs. We found the mortality rate was not increased in IC patients. This reinforces that there is a potential protective effect of immunosuppression against a possible hyperinflammation host response observed in SARS-CoV-2 infection and warrants reconsideration of discontinuing systematically immunosuppressive drugs in patients with severe underlying diseases.

Declarations

ACKNOWLEDGEMENTS

Contributors:

Drs Monreal and Sainz de la Maza had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Monreal, Sainz de la Maza, Masjuan.

Acquisition, analysis or interpretation of data: Monreal, Sainz de la Maza, Gullón, Natera-Villalba, Chico-García, Beltrán-Corbellini, Martínez-Sanz, García-Barragán, Buisán, Toledano, Alonso-Canovas, Pérez-Torre, Matute-Lozano, López-Sendón, García-Ribas, Corral, Fortún, Montero-Erasquín, Manzano, Máiz-Carro, Lucienne Costa-Frossard, Masjuan.

Drafting of the manuscript: Monreal, Sainz de la Maza, Gullón, Natera-Villalba, Masjuan.

Critical revision of the manuscript for important intellectual content: Monreal, Sainz de la Maza, Gullón, Natera-Villalba, Chico-García, Beltrán-Corbellini, Martínez-Sanz, García-Barragán, Buisán, Toledano, Alonso-Canovas, Pérez-Torre, Matute-Lozano, López-Sendón, García-Ribas, Corral, Fortún, Montero-Erasquín, Manzano, Máiz-Carro, Lucienne Costa-Frossard, Masjuan.

Statistical analyses: Monreal, Gullón.

Administrative, technical or material support: Monreal, Sainz de la Maza, Gullón, Natera-Villalba, Chico-García, Beltrán-Corbellini, Martínez-Sanz, García-Barragán, Buisán, Toledano, Alonso-Canovas, Pérez-Torre, Matute-Lozano, López-Sendón, García-Ribas, Corral, Fortún, Montero-Erasquín, Manzano, Máiz-Carro, Lucienne Costa-Frossard, Masjuan.

Study supervision: Masjuan.

Funding/Support: *The authors received no financial support for the research, authorship, and/or publication of this article.*

CONFLICT OF INTERESTS

The authors report no conflict of interests.

References

1. Novel coronavirus – China. Available at: <http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>. Accessed April 11, 2020.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506. doi: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;13:e200994. [Epub ahead of print]. doi: <https://doi.org/10.1001/jamainternmed.2020.0994>
4. Siddiqi HK, Meehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. *J Heart Lung Transplant*. 2020; ;39(5):405-407. [Epub ahead of print]. doi: <https://doi.org/10.1016/j.healun.2020.03.012>
5. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. *Liver Transpl*. 2020;26:832-834. [Epub ahead of print]. doi: <https://doi.org/10.1002/LT.25756>
6. COVID-19 situation in Spain. Available at: <https://covid19.isciii.es/>. Accessed April 11, 2020.
7. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. Available at: <https://apps.who.int/iris/handle/10665/330854>. Accessed April 11, 2020.
8. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*. 2012;307:2526-33. doi: <https://doi.org/10.1001/jama.2012.5669>
9. Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. *Curr Opin Infect Dis*. 2012;25:423-30. doi: <https://doi.org/10.1097/QCO.0b013e328355660b>
10. Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. *Clin Infect Dis*. 2014;58:214-24. doi: <https://doi.org/10.1093/cid/cit725>.
11. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet*. 2015;386:995-1007. doi: [https://doi.org/10.1016/S0140-6736\(15\)60454-8](https://doi.org/10.1016/S0140-6736(15)60454-8)
12. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis*. 2013;13:752-61. doi: [https://doi.org/10.1016/S1473-3099\(13\)70204-4](https://doi.org/10.1016/S1473-3099(13)70204-4)
13. Garbati MA, Fagbo SF, Fang VJ, et al. A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS

- Coronavirus or Other Causes. PLoS One. 2016;11:e0165978. doi: <https://doi.org/10.1371/journal.pone.0165978>
14. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. *Lancet Infect Dis*. 2018;18:e217-27. doi: [https://doi.org/10.1016/S1473-3099\(18\)30127-0](https://doi.org/10.1016/S1473-3099(18)30127-0)
 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395:1054-62. doi: [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
 16. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020;46:846-848. [Epub ahead of print]. doi: <https://doi.org/10.1007/s00134-020-05991-x>
 17. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020; 323:1061-1069. [Epub ahead of print]. doi: <https://doi.org/10.1001/jama.2020.1585>
 18. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395:1033-4. [Epub ahead of print]. doi: [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0).
 19. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. *Clin Immunol*. 2020;214:108393. [Epub ahead of print]. doi: <https://doi.org/10.1016/j.clim.2020.108393>.
 20. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020;21:335-337. doi: [https://doi.org/10.1016/S1470-2045\(20\)30096-6](https://doi.org/10.1016/S1470-2045(20)30096-6).
 21. He W, Chen L, Chen L et al. COVID-19 in persons with haematological cancers. 2020;34:1637-1645. <https://doi.org/10.1038/s41375-020-0836-7>.
 22. Martín-Moro F, Marquet J, Piris M et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. *Br J Haematol*. 2020;7:10.1111/bjh.16801. <https://doi.org/10.1111/bjh.16801>
 23. Pereira MR, Mohan S, Cohen DJ et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. *Am J Transplant*. 2020;24:10.1111/ajt.15941. <https://doi.org/10.1111/ajt.15941>.
 24. Akalin E, Azzi Y, Bartash R et al. Covid-19 and Kidney Transplantation. *N Engl J Med*. 2020;24:NEJMc2011117. <https://doi.org/1056/NEJMc2011117>.
 25. The OpenSAFELY Collaborative, Williamson E, Walker AJ, Bhaskaran KJ et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 05.06.20092999. <https://doi.org/10.1101/2020.05.06.20092999>.
 26. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. *Virol Sin*. 2020;3:1-6. [Epub ahead of print]. doi:

<https://doi.org/10.1007/s12250-020-00207-4>.

27. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol*. 2004;136:95-103. doi: <https://doi.org/10.1016/j.clim.2020.108393>.
28. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. *J Exp Med*. 2020;1;217(6):e20200678. <https://doi.org/10.1084/jem.20200678>.
29. Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri S, Bayry J. Autoimmunity as a Predisposition for Infectious Diseases. *PLoS Pathog*. 2010;4;6(11):e1001077. <https://doi.org/10.1371/journal.ppat.1001077>.
30. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020;e201017. [Epub ahead of print]. doi: <https://doi.org/10.1001/jamacardio.2020.1017>.
31. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091. doi: <https://doi.org/10.1136/bmj.m1091>.
32. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004;203:631-7. doi: <https://doi.org/10.1002/path.1570>
33. Wolf D, Skup M, Yang H, et al. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. *Clin Ther*. 2017;39:849-862.e6. doi: <https://doi.org/10.1016/j.clinthera.2017.03.005>
34. Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. *Neurol Ther*. 2019;8:241-50. doi: <https://doi.org/10.1007/s40120-019-00160-9>

Table

Demographic, clinical and laboratory characteristics at admission				
	Total (n=138)	Immunosuppressed (n=27)	Non- immunosuppressed (n=111)	p Value
Age (years), median (IQR)	68 (54 – 78)	66 (48 – 80)	68 (56 – 78)	0.58
Men, No. (%)	95 (68.8%)	18 (66.7%)	77 (69.4%)	0.48
Comorbidities, No. (%)				
None	28 (20.3%)	0	28 (25.2%)	0.002
Hypertension	70 (50.7%)	16 (59.3%)	54 (48.7%)	0.22
Diabetes type 2	36 (26.1%)	4 (14.8%)	31 (27.9%)	0.12
Obesity (BMI ≥30)	39 (28.3%)	6 (22.2%)	33 (29.7%)	0.49
Cardiovascular disease*	33 (23.9%)	8 (29.6%)	25 (22.5%)	0.47
Chronic renal disease	18 (13.0%)	7 (25.9%)	11 (9.91%)	0.050
Chronic liver disease	9 (6.5%)	3 (11.1%)	6 (5.4%)	0.38
Chronic respiratory disease†	32 (23.2%)	5 (18.5%)	27 (24.3%)	0.62
Autoimmune disease	19 (13.8%)	16 (59.3%)	3 (2.7%)	<0.001
Active malignancy	15 (10.9%)	5 (18.5%)	10 (9%)	0.17
Malignancy in remission	12 (8.7%)	4 (14.8%)	8 (7.2%)	0.25
Organ transplant	5 (3.6%)	5 (18.5%)	0	<0.001
Time from symptoms onset to admission (days), median (Q1, Q3)	7 (4 – 11)	6 (4 – 11)	7 (4 – 11)	0.64
Respiratory parameters				
SatO2 (%), median (Q1, Q3)	93 (88 – 96)	95 (92 – 98)	92 (87 – 96)	0.07
PaO2 (mm Hg), No. with data	92	13	79	
Median (Q1, Q3)	57 (51 – 66)	62 (52 – 73)	57 (51 – 66)	0.55
PaO2/FiO2 (mm Hg), median (Q1, Q3)	267 (233 – 310)	271 (232 – 348)	267 (233 – 310)	0.75
Pneumonia				0.19
None	6 (4.3%)	2 (7.4%)	4 (3.6%)	
Unilateral	19 (13.8%)	6 (22.2%)	13 (11.7%)	
Bilateral	113 (81.9%)	19 (70.4%)	94 (84.7%)	
CURB-65 score, median (IQR)	1,5 (1 – 2)	1 (1 – 2)	2 (1 – 2)	0.48
qSOFA, median (Q1, Q3)	1 (0 – 1)	1 (0 – 1)	1 (0 – 1)	0.78
Blood analysis, median (Q1, Q3)				
White blood cell, /μL	6515 (4850 – 9140)	6470 (4250 – 9730)	6560 (4860 – 9110)	0.74
Neutrophil, /μL	4935 (3420 – 7540)	4550 (2850 – 7950)	4980 (3500 – 7400)	0.39
Lymphocyte, /μL	855 (620 – 1210)	810 (560 – 1140)	870 (630 – 1250)	0.62
C-reactive protein, mg/L	113 (51.3 – 173.4)	74.5 (33.3 – 144.9)	119.1 (56.7 – 186.1)	0.08
D-dimer (μg/L), No. with data	110	20	90	
Median (Q1, Q3)	794.5 (535 – 1447)	897.5 (606.5 – 1651)	784 (482 – 1399)	0.44
Ferritine (ng/mL), No. with data	57	5	52	
Median (Q1, Q3)	961 (544 –	610.7 (228 – 1084)	972 (564.5 – 1863)	0.28

	1836)			
Bacterial co-infection, No. (%)	20 (14.5%)	4 (14.8%)	16 (14.4%)	>0.99
Treatments administered, No. (%)				
Lopinavir/Ritonavir	117 (84.8%)	19 (70.4%)	98 (88.2%)	0.033
Hydroxychloroquine	136 (98.6%)	26 (96.3%)	110 (99.1%)	0.35
Antibiotics	94 (69.1%)	19 (70.3%)	75 (68.8%)	>0.99
Azithromycin	95 (68.8%)	16 (59.3%)	79 (71.2%)	0.25
Corticosteroids	85 (61.6%)	13 (48.2%)	72 (64.9%)	0.13
Tocilizumab	16 (11.6%)	1 (3.7%)	15 (13.5%)	0.20
Anakinra	3 (2.2%)	0	3 (2.7%)	>0.99

Abbreviations: BMI: body mass index. CURB-65: Confusion, Urea >7 mmol/L, Respiratory Rate ≥ 30 /min, Systolic (≤ 90 mmHg) or Diastolic (≤ 60 mmHg) blood pressure and Age ≥ 65 years. FiO₂: fraction of inspired oxygen. NS: non-significant. PaO₂: arterial partial pressure of oxygen. Q1, Q3: quartile 1, quartile 3. qSOFA: quick Sepsis-related Organ Failure Assessment. SatO₂: oxygen saturation. *Heart failure, myocardopathy, ischemic and moderate-severe valvular heart diseases. †Chronic obstructive pulmonary disease, obstructive sleep apnea-hypopnea syndrome and diffuse interstitial lung disease.

Appendice

The COVID-HRC group [Masjuan, J; Fortún, J; Montero-Erasquín, B; Manzano, L; Máiz-Carro, L; Sánchez-García, EM; Hidalgo, F; Domínguez, AR; Pérez-Molina, JA; Sánchez-Sánchez, O; Comeche, B; Monge-Maillo, B; Barbolla-Díaz, I; Aranzábal Orgaz, L; Cobo, J; Rayo, I; Fernández-Golfín, C; González, E; Rincón-Díaz, LM; Ron, R; Mateos-Muñoz, B; Navas, E; Moreno, J; Norman, J; Serrano, S; Quereda Rodríguez-Navarro, C; Vallés, A; Herrera, S; Mateos del Nozal, J; Moreno-Cobo, MA; Gioia, F; Concejo-Badorrey, MC; Ortiz Barraza, EY; Moreno, A; Chamorro, S; Casado, JL; Almonacid, C; Nieto, R; Diz, S; Moreno, E; Conde, M; Hermida, JM; López, M; Monreal, E; Sainz de la Maza, S; Costa-Frossard, L; Natera-Villalba, E; Chico-García, JL; Beltrán-Corbellini, Á; Martínez-Sanz, J; García-Barragán, N; Buisán, J; Toledano, R; Alonso-Canovas, A; Pérez-Torre, P; Matute-Lozano, MC; López-Sendón, JL; García-Ribas, G; Corral, Í]. The Coronavirus disease 2019 – Hospital Ramón y Cajal (COVID-HRC).

Figures

Figure 1

Study selection. RT-PCR: reverse transcriptase–polymerase chain reaction.

Figure 2

Primary and secondary endpoints. The figure shows the crude (red line) and adjusted (blue line) OR of the primary (moderate or severe ARDS) and secondary (ARDS, MV/NIV, a composite of MV/NIV and death

and death) endpoints. ARDS: acute respiratory distress syndrome. MV: mechanical ventilation. NIV: non-invasive ventilation. OR: odds ratio.

Figure 3

Time to moderate or severe ARDS. ARDS: acute respiratory distress syndrome.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementalMaterial.docx](#)